DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

Information source: Anesiva, Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atopic Dermatitis

Intervention: NF-kappaB Decoy (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Anesiva, Inc.

Official(s) and/or principal investigator(s):
Andria Langenberg, MD, Study Director, Affiliation: Anesiva, Inc.

Summary

The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.

Clinical Details

Official title: A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: To evaluate the safety and tolerability of twice-daily topical application of three concentrations of NF-kappaB Decoy in adult subjects with mild-to-moderate atopic dermatitis

Secondary outcome:

To make a preliminary evaluation of the efficacy of the topical NF-kappaB Decoy in the treatment of mild-to-moderate atopic dermatitis in adult subjects

To evaluate the systemic pharmacokinetic (PK) profile of NF-kappaB Decoy

Detailed description: This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety of repeated application of three concentrations of NF-kappaB Decoy in approximately 75 subjects with mild-to-moderate atopic dermatitis. The face, hands, feet, scalp, or groin may NOT be treated. Other treatment agents are currently available for atopic dermatitis but present significant potential side effects (topical steroids) or are potent immunosuppressives (topical calcineurin inhibitors) with pending longer-term safety data. NF-kappaB Decoy is a double-stranded deoxyribonucleic acid (DNA) oligodeoxynucleotide that mimics the NF-kappaB binding sequence on the chromosomal DNA, thereby inhibiting the production of the inflammatory response triggered by NF-kappaB. This mechanism of action presents a unique treatment modality. A comprehensive series of nonclinical data have produced promising results.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Are 18 through 65 years of age and sign an informed consent

- Have been given a diagnosis of mild to moderate atopic dermatitis as defined by:

*Pruritus; *Eczematous dermatitis (acute, subacute, chronic) involving at least current or prior flexural lesions with chronic or relapsing course; *Early age of onset (prior to 10 years of age, by history); *Personal or family history of atopy

- If receiving antihistamines, are on a stabilized dose, and expect to maintain this

dose throughout the study

- Are females or males of reproductive potential who are compliant in using adequate

birth control or are females or males not of reproductive potential Exclusion Criteria:

- Have concomitant dermatologic or medical condition(s) which may interfere with the

investigator's ability to evaluate the subject's response to the study drug

- Have immunocompromised status (such as known human immunodeficiency virus infection)

- Have any clinically significant abnormal clinical laboratory test results at

Screening

- Have a history of malignancy not in remission for at least 5 years excluding basal

cell carcinoma and nonperiorificial squamous cell carcinoma of the skin

- Have an active intercurrent infection

- Have applied any topical medication (including corticosteroid, calcineurin inhibitor,

topical H1 and H2 antihistamines, topical antimicrobials, other medicated topical agents) or herbal preparation to the area selected for treatment within 1 week of the Day 1 visit; have used any systemic antibiotic within 1 week prior to the Day 1 visit; have used any systemic treatment for atopic dermatitis (including systemic corticosteroids, nonsteroidal immunosuppressants, or treatment with light) within 4 weeks prior to the Day 1 visit; have used an investigational drug for any reason within 4 weeks of the Day 1 visit; have used intranasal and/or inhaled corticosteroids at doses > 2 mg prednisone or equivalent per day within 4 weeks of the Day 1 visit; or have used immunosuppressive or immunomodulating drugs such as etanercept, alefacept, or infliximab within 16 weeks prior to Day 1

- Have a history of hypersensitivity or allergic reactions to parabens or any other

ingredient in the vehicle formulation

- If female, are pregnant or lactating, or intend to become pregnant during the study

period

- If male, have a female partner who is pregnant or lactating, or intends to become

pregnant during the study period

- Have any reason which, in the opinion of the investigator, interferes with the

ability of the subject to participate in or complete the trial, or which places the subject at undue risk

Locations and Contacts

University of Miami Skin Research, Miami, Florida 33136, United States

Minnesota Clinical Study Center, Fridley, Minnesota 55432, United States

Mount Sinai School of Medicine, New York, New York 10029, United States

Helendale Dermatology & Medical Spa, LLP, Rochester, New York 14609, United States

Oregon Health & Science University, Department of Dermatology, Portland, Oregon 97201, United States

Derm Research, Inc., Austin, Texas 78759, United States

Center for Clinical Studies, Houston, Texas 77030, United States

Center for Clinical Studies, South Houston, Texas 77058, United States

Madison Skin & Research, Inc., Madison, Wisconsin 53719, United States

Additional Information

Starting date: March 2005
Last updated: November 18, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017